[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Interferon - Biosimilar Insight, 2020

August 2020 | 70 pages | ID: I8E22DC15D76EN
DelveInsight

US$ 1,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 48-72 hours

DelveInsight’s, “Interferon– Biosimilar Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Interferon Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Interferon Understanding

Interferon: Overview

Interferons are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses. Interferon is further categorized in its variants.

Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in E. coli in the laboratory of Charles Weissmann at the University of Zurich, in 1980.

Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis. It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some claims have been made that Interferons produce about an 18–38% reduction in the rate of MS relapses.

Interferon Biosimilars: Drugs Chapters

This segment of the Interferon report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interferon Biosimilars: Marketed Drugs
  • Bioferon: Biosidus
Bioferon is being developed by Biosidus. The drug is being approved for the treatment of Cancer; Hepatitis B; Hepatitis C; Kaposi's sarcoma.

Further product details are provided in the report……..

Interferon Biosimilars: Emerging Drugs
  • Interferon beta-1b biosimilar: Harvest Moon Pharmaceuticals
Harvest Moon Pharmaceuticals is developing Interferon beta-1b biosimilar for the treatment of Multiple sclerosis.

Further product details are provided in the report……..

Interferon: Therapeutic Assessment

This segment of the report provides insights about the different Interferon biosimilars segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Interferon
There are approx. 10+ key companies which are developing the therapies for Interferon.
  • Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
  • Marketed stage products
  • Late stage products (BLA Filed and Phase III)
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Interferon pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Subcutaneous
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal antibodies
  • Peptide
  • Protein
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interferon: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Interferon biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interferon biosimilar drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Interferon R&D. The therapies under development are focused on novel approaches to treat/improve Interferon.
Interferon Biosimilars Report Insights
  • Interferon Biosimilar Pipeline Analysis
  • Therapeutic Assessment
  • Sales Assessment
  • Unmet Needs
  • Impact of Drugs
Interferon Biosimilar Report Assessment
  • Marketed Product profiles
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Sales Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Interferon Biosimilars?
  • How many Interferon biosimilars are developed by each company?
  • How many emerging biosimilars are in mid-stage, and late-stage?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interferon biosimilars therapeutics?
  • What are the clinical studies going on for Interferon biosimilars and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Zydus Cadila
  • Reliance Life Sciences
  • Profarma
  • Harvest Moon Pharmaceuticals
  • Dong-A ST
  • CinnaGen
  • BioPartners
  • Biocad
  • Amega Biotech
Key Products
  • MAB 2
  • ReliBeta
  • PF-08
  • Interferon beta-1b biosimilar
  • DA-3051
  • Cinno Vex
  • ReciGen
  • Bioferon
  • Inmutag
  • Alpheon
  • BCD-033
  • Megavex
1. KEY INSIGHTS

2. INTERFERON BIOSIMILARS: SNAPSHOT

3. EXECUTIVE SUMMARY

3.1. Overview
3.2. The Basics of Biologics.
3.3. Biosimilars are not the Same as Generic Drugs
3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?
3.5. What Patients Need to Know About Biosimilars

4. REGULATORY OUTLOOK FOR BIOSIMILARS

4.1. North America
  4.1.1. US
  4.1.2. Canada
4.2. Europe
4.3. Asia Pacific
  4.3.1. China
  4.3.2. India
  4.3.3. Japan
  4.3.4. South Korea
  4.3.5. Australia
4.4. Rest Of The World
  4.4.1. Brazil
  4.4.2. Mexico
  4.4.3. Argentina
  4.4.4. Saudi Arabia
*More Countries would be added in the final report

5. INTERFERON (REFERENCE PRODUCT: AVONEX)

5.1. Drug Profile
5.2. Product Overview
5.3. Regulatory Approvals and Launch
5.4. Indications
5.5. Mechanism of Action
5.6. Dosage and Administration
5.7. Dosage and Strengths
5.8. Dose Modification
5.9. Route of Synthesis
5.10. Pharmacology
5.11. Pharmacodynamics
5.12. Pharmacokinetics
5.13. Adverse Reactions
5.14. Product Snapshot
5.15. Development Milestones

6. RESEARCH AND DEVELOPMENT

6.1. Clinical Trials Information
6.2. Safety and Efficacy

7. AVONEX BIOSIMILAR: EMERGING OPPORTUNITIES

*More variants of Interferon would be added in the final report

8. INTERFERON: BIOSIMILARS ASSESSMENT

8.1. Assessment by Product Type
8.2. Assessment by Route of Administration
8.3. Assessment by Molecule type
8.4. Sales Assessment

9. INTERFERON BIOSIMILARS PROFILES: BY COMPANY

  9.1.1. Zydus Cadila
    9.1.1.1. MAB 2: Zydus Cadila
      9.1.1.1.1. Product Information
      9.1.1.1.2. Research and Development
      9.1.1.1.3. Other Development Activities
      9.1.1.1.4. General Description Table
  9.1.2. Profarma
    9.1.2.1. PF-08: Profarma
      9.1.2.1.1. Product Information
      9.1.2.1.2. Research and Development
      9.1.2.1.3. Other Development Activities
      9.1.2.1.4. General Description Table
*More Companies and products would be added in the final report

10. INTERFERON BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY

11. INTERFERON BIOSIMILARS: COMPETITIVE LANDSCAPE

  11.1.1. Overview
  11.1.2. Market Share Analysis
  11.1.3. Competitive Scenario
    11.1.3.1. Product Launches and approval
    11.1.3.2. Partnerships, Collaborations and Agreements
    11.1.3.3. Acquisitions
    11.1.3.4. Expansions
    11.1.3.5. Patent Expiration of Biologics
*More information would be added in the final report

12. MARKET DRIVERS

13. MARKET BARRIERS

14. SWOT ANALYSIS

15. APPENDIX

15.1. Research Methodology
  15.1.1. Coverage
  15.1.2. Secondary Research

16. BIBLIOGRAPHY

17. DELVEINSIGHT CAPABILITIES

18. DISCLAIMER

19. ABOUT DELVEINSIGHT

LIST OF TABLES

Table 1 Total Products for Interferon
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


LIST OF FIGURES

Figure 1 Total Products for Interferon
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


More Publications